Comparative Pharmacology
Head-to-head clinical analysis: ANDROGEL versus ANDROID 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROGEL versus ANDROID 5.
ANDROGEL vs ANDROID 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
None Documented
None Documented
The terminal elimination half-life of testosterone from AndroGel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Category C
Category C
Androgen
Androgen